ADC治疗相关眼表毒性:肿瘤精准治疗中的新挑战
ADC therapy-related ocular surface toxicity:an emerging challenge in precision cancer therapy
摘要
抗体药物偶联物推动肿瘤治疗进入精准治疗时代,然而其眼表毒性作为"靶向-脱靶"矛盾的典型表征,已成为制约临床获益的关键瓶颈.毒性机制涉及靶抗原交叉表达、载荷旁效应及泪膜稳态失衡等病理过程,临床以角膜上皮微囊病变、点状角膜炎及泪膜功能障碍为主要表现.当前管理策略正从被动处置转向机制驱动的主动防控,强调基线评估、动态监测与多学科联合管理.不同抗体药物偶联物毒性谱的差异,为药物的结构优化与患者的个体化分层管理提供了重要线索.深化分子机制研究、建立影像组学早期预警体系,是实现疗效与眼表安全二者平衡的未来方向.
Antibody-drug conjugates(ADCs)have propelled cancer therapy into the era of precision medicine;however,their ocular surface toxicity,as a prototypical manifestation of the"on-target,off-tumor"paradox,has emerged as a critical bottleneck constraining clinical benefit.The underlying mechanisms involve pathological processes including target antigen cross-expression,payload bystander effects,and tear film home-ostasis disruption,with predominant clinical manifestations of corneal epithelial microcyst-like changes,punc-tate keratitis,and tear film dysfunction.The management paradigm is shifting from passive intervention to mechanism-driven proactive prevention,emphasizing baseline evaluation,dynamic monitoring,and integrated multidisciplinary management.Heterogeneity in toxicity profiles across distinct ADC agents provides crucial clues for structural optimization of drugs and individualized stratified management of patients.Deepening mech-anistic research and establishing radiomics-based early warning systems represent the future direction toward achieving a balance between antitumor efficacy and ocular surface safety.
年,卷(期):
2026, 35(4)
机标分类号:
R734.2
G641
F114.41
在线出版日期:
2026年8月20日